Hans Gelderblom
Universiteit Leiden
H-index: 106
Europe-Netherlands
Top articles of Hans Gelderblom
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Individualized Dosing Patterns in the Treatment of Older Patients with Gastrointestinal Stromal Tumors: Results of a Registry-Based Observational National Cohort Study … | Drugs & Aging | Roos F Bleckman K Esther Broekman Evelyne Roets Mohammed Mohammadi Ingrid ME Desar | 2024/2 |
141TiP Cemiplimab treatment in patients with locally advanced and metastatic secondary angiosarcomas (CEMangio): A phase II clinical trial in progress | ESMO Open | S van Ravensteijn JJ de Haan H Gelderblom Y Versleijen-Jonkers F Speetjens | 2024/3/1 |
Abstract CT064: Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a phase 1 dose escalation study | Cancer Research | Anne Bellon Omar Saavedra Ingrid M Desar Mathilde Jalving Jourik A Gietema | 2024/4/5 |
Health-related quality of life in patients with gastrointestinal stromal tumor: data from a real-world cohort compared with a normative population | ESMO Real World Data and Digital Oncology | D van de Wal D den Hollander IME Desar H Gelderblom AW Oosten | 2024/6/1 |
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real … | JCO Precision Oncology | Allan Hackshaw Otto Fajardo Urania Dafni Hans Gelderblom Pilar Garrido | 2024/1 |
Evaluation of response to neoadjuvant chemotherapy in osteosarcoma using dynamic contrast-enhanced MRI: development and external validation of a model | Cancer Research | J Choi K Kim W Kim S Lee H Lim | 2009/1/15 |
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT … | ESMO Open | JY Blay RL Jones H Gelderblom S George P Schöffski | 2024/3/1 |
Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor–stroma ratio in colon cancer | ESMO open | M Polack MA Smit GW van Pelt AGH Roodvoets E Meershoek-Klein Kranenbarg | 2024/4/1 |
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP) | European Journal of Cancer | Ilse AC Spiekman Laurien J Zeverijn Birgit S Geurts Karlijn Verkerk Soemeya F Haj Mohammad | 2024/5/1 |
Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses … | John Raymond Zalcberg Robin Lewis Jones Jean-Yves Blay Suzanne George Hans Gelderblom | 2024/1/20 | |
58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment | ESMO Open | S Stacchiotti AJ Wagner IC Carrasco Garcia M Cesari M Gordon | 2024/3/1 |
Incidence and centralization of chordoma in the Netherlands: A nationwide study between 1991 and 2020 | Cancer Epidemiology | A Lipplaa RJP van der Wal ADG Krol WC Peul JVMG Bovée | 2024/4/1 |
Financial difficulties experienced by patients with gastrointestinal stromal tumours (GIST) in the Netherlands: data from a cross-sectional multicentre study | Supportive Care in Cancer | Deborah van de Wal Dide den Hollander Ingrid ME Desar Hans Gelderblom Astrid W Oosten | 2024/5 |
Referral patterns of GIST patients: data from a nationwide study | ACTA ONCOLOGICA | Evelyne Roets Nikki S Ijzerman Vincent KY Ho Ingrid ME Desar Anna KL Reyners | 2024/2/14 |
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial | Nature medicine | Michael C Heinrich Robin L Jones Suzanne George Hans Gelderblom Patrick Schöffski | 2024/1/5 |
A genome‐wide association study of endoxifen serum concentrations and adjuvant tamoxifen efficacy in early‐stage breast cancer patients | Clinical Pharmacology & Therapeutics | Anabel Beatriz Sanchez‐Spitman Stefan Böhringer Vincent Olaf Dezentjé Hans Gelderblom Jesse Joachim Swen | 2024/3/19 |
Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol | Clinical Cancer Research | Birgit S Geurts Laurien J Zeverijn Lindsay VM Leek Jade M van Berge Henegouwen Louisa R Hoes | 2024/4/17 |
The variable genomic landscape during osteosarcoma progression: insights from a longitudinal WGS analysis | medRxiv | Debora M Meijer Dina Ruano Inge H Briaire-de Bruijn Pauline M Wijers-Koster Michiel AJ van de Sande | 2024 |
Active surveillance of diffuse-type tenosynovial giant cell tumors: A retrospective, multicenter cohort study | European Journal of Surgical Oncology | Geert Spierenburg Eric L Staals Emanuela Palmerini Robert Lor Randall Steven W Thorpe | 2024/2/1 |
Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum | Sarcoma | Victor Rechl Andreas Ranft Vivek Bhadri Benedicte Brichard Stephane Collaud | 2024/3/16 |
